Patents by Inventor Roland Stragies

Roland Stragies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210030657
    Abstract: The present invention relates to a dermal filler composition based on crosslinked hyaluronic acid, calcium phosphate material particles and carboxymethyl cellulose. The present invention further provides a process for preparing said dermal filler composition, and its use in cosmetic treatments such as for improvement of skin quality.
    Type: Application
    Filed: April 12, 2019
    Publication date: February 4, 2021
    Inventors: Roland STRAGIES, Nadine HAGEDORN, Lubin BELKOVI
  • Publication number: 20190269582
    Abstract: The present invention generally relates to the field of hyaluronic acid (HA) dermal fillers, and more specifically to methods for preparing crosslinked HA-based compositions in the form of a gel comprising high-temperature dialysis and/or crosslinking in the presence of phosphate and an alkaline metal halide salt. The present invention further relates to crosslinked HA-based gel compositions prepared by said methods and their use as dermal fillers in aesthetic applications such as wrinkle treatments.
    Type: Application
    Filed: November 2, 2017
    Publication date: September 5, 2019
    Applicant: Merz Pharma GmbH & Co. KGaA
    Inventors: Nadine HAGEDORN, Roland STRAGIES, Lubin BELKOVI, Radia EL-BANNA
  • Patent number: 10335512
    Abstract: The present invention relates to injectable dermal filler compositions in the form of a gel, comprising hyaluronic acid (HA), carboxymethyl cellulose (CMC) and, optionally, microparticles such as calcium hydroxyapatite (CaHAP) microparticles. The injectable dermal filler compositions have improved rheological properties while at the same time have low extrusion forces. The present invention further relates to a method for preparing such injectable dermal filler compositions and their use for cosmetic and therapeutic purposes.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: July 2, 2019
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Nadine Hagedorn, Roland Stragies, Franck Villain, Lubin Belkovi, Radia El-Banna
  • Publication number: 20170333596
    Abstract: The present invention relates to injectable dermal filler compositions in the form of a gel, comprising hyaluronic acid (HA), carboxymethyl cellulose (CMC) and, optionally, microparticles such as calcium hydroxyapatite (CaHAP) microparticles. The injectable dermal filler compositions have improved rheological properties while at the same time have low extrusion forces. The present invention further relates to a method for preparing such injectable dermal filler compositions and their use for cosmetic and therapeutic purposes.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 23, 2017
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: NADINE HAGEDORN, ROLAND STRAGIES, FRANCK VILLAIN, LUBIN BELKOVI, RADIA EL-BANNA
  • Patent number: 8927534
    Abstract: The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; ? is a radical of formula (II), R2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: January 6, 2015
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
  • Patent number: 8501787
    Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: August 6, 2013
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
  • Patent number: 8309735
    Abstract: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a linker and ? is a radical of formula (II) and their use for the inhibition of integrin.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: November 13, 2012
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
  • Publication number: 20110065760
    Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.
    Type: Application
    Filed: November 23, 2009
    Publication date: March 17, 2011
    Applicant: Jerini AG
    Inventors: Jochen KNOLLE, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
  • Publication number: 20090203745
    Abstract: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a linker and ? is a radical of formula (II) and their use for the inhibition of integrin.
    Type: Application
    Filed: May 14, 2007
    Publication date: August 13, 2009
    Applicant: Jerini AG
    Inventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
  • Publication number: 20090104116
    Abstract: The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; ? is a radical of formula (II), R2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.
    Type: Application
    Filed: January 31, 2007
    Publication date: April 23, 2009
    Applicant: JERINI AG
    Inventors: Gunter Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
  • Publication number: 20070155712
    Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.
    Type: Application
    Filed: March 24, 2005
    Publication date: July 5, 2007
    Applicant: Jerini AG
    Inventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
  • Publication number: 20070054904
    Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and —S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.
    Type: Application
    Filed: September 18, 2003
    Publication date: March 8, 2007
    Applicant: Jerini AG
    Inventors: Jochen Knolle, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
  • Publication number: 20060252813
    Abstract: The present invention is related to a compound of formula (I): A-B-E-D (I), wherein: A is selected from the group consisting Ra-L1-K-L2; and (II) B is either present or absent, but if B is present then B is (III), E is (IV), D is selected from the group comprising —(CR1Rm)rC(O)H, —(CR1Rm)rC—N, —CR1Rm)rNHNHC(O)NR5R6, —(CR1Rm)rC(O)(CRnRo)rc(O)OR7, —(CR1Rm)rC(O)(CrnRo)rC(O)NR8R9, —(CR1Rm)rCH(OH)(CrnRo)rC(O)U, —(CR1Rm)rC(O)W—(CR1Rm)rC(O)CH2W, —(CR1Rm)rC(O)haloalkyl, and —(CR1Rm)rC(O)(CRnRo)r—CHN2, and the use of said compounds as an inhibitor to rotamases.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 9, 2006
    Inventors: Jochen Knolle, Mike Schumtkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Roland Stragies